Alteogen Inc

Common Name
Alteogen
Country
South Korea
Sector
Healthcare
Industry
Biotechnology
Employees
155
Ticker
196170
Exchange
KOREA EXCHANGE
Description
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth horm...

Alteogen's Financial Statements Preview

Below are the financial statements of Alteogen, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of KRW
2024 2024-01-01 - 2024-12-31
2023 2023-01-01 - 2023-12-31
2022 2022-01-01 - 2022-12-31
Revenue (sales)
102.85a
96.52a
28.81a
Cost of sales
-38.79a
-65.32a
-24.28a
Gross profit
64.07a
31.2a
4.53a
Selling and administrative expenses
-38.67a
-40.94a
-33.9a
Operating income (loss)
25.4a
-9.74a
-29.37a
Other income
8.77a
9.91a
17.11a
Other losses
-4.74a
-8.39a
-1.15a
Finance income
7.87a
5.38a
3.87a
Finance costs
-0.7a
-0.72a
-0.43a
Profit (loss) before income tax
36.61a
-3.56a
-9.97a
Income tax expense (benefit)
-24.08a
-0.02a
-0.11a
Net income (loss)
60.69a
-3.58a
-10.08a
Download Data

Verified Sources Behind Alteogen’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alteogen’s data sources below and access millions more through our Disclosure Search.

a. Alteogen's Annual Report 2024
a. Alteogen's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?